Boehringer Ingelheim has announced a new collaboration with OSE Immunotherapeutics that will aim to jointly develop a new immuno-oncology therapy.
The exclusive worldwide collaboration and licence agreement will focus on the development of OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells, which could be used for the treatment of advanced solid tumours.
“Boehringer Ingelheim is partnering with OSE Immunotherapeutics on the development of a new immuno-oncology therapy.“
OSE-172 has the potential to enhance anti-tumour immunity by improving T cell activity, and is currently in late-stage preclinical development. It has shown potential benefits in the treatment of multiple cancer types.
Boehringer Ingelheim has acquired global rights to develop, register and commercialise OSE-172, with OSE Immunotherapeutics to receive a EUR 15 million (GBP 13.1 million) upfront payment, as well as more than EUR 1.1 billion based on the achievement of certain milestones.
Dr Jonathon Sedgwick, global head of cancer immunology and immune modulation research at Boehringer Ingelheim, said: "We are dedicated to developing groundbreaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical